10 Wall Street Analysts Think Argenx Stock Is Headed to At Least $1,200 -- Is the Stock a Buy Now?
Argenx SE (ARGX) has a market cap near $60B. 10 analysts predict its stock, priced at $919, will reach at least $1,200 in 12 months. Some analysts set targets up to $1,415. The company reported $1.5B in Q3 sales, driven by Vyvgart and Vyvgart Hytrulo. Argenx faces clinical trial risks and China sales challenges.
How this was made
The 30-second read
Why it matters
The analyst consensus upgrade may buoy the stock modestly, yet the lack of a concrete catalyst limits actionable trading ideas.
Market read
Analyst optimism may lift sentiment, but without new data releases the story offers limited trading impetus.
What to watch
Recent sales weakness in China and reliance on pending trial results pose downside risks not captured by price targets.
Background
Argenx reported a 60% YoY increase in quarterly product sales and announced positive late‑stage trial data for Vyvgart Hytrulo, but the article focuses on analyst price‑target revisions.
Ticker impact
Ten Wall Street analysts raised 12‑month price targets for Argenx to $1,200‑$1,415, indicating a bullish outlook and potential upside of 30‑50% from the current $919 price.
modest upward pressure as market prices in higher target expectations
Targets are forward‑looking and not tied to a new earnings release or regulatory event; price moves will depend on future data releases.
Market effects
The biotech sector may see modest optimism as analysts lift targets for a mid‑cap player, but no sector‑wide catalyst is present.
Limited to U.S. biotech investors; no broader regional effect.
Low; the story is company‑specific without global macro implications.
Counterpoint
Analyst upgrades could be premature if upcoming Phase 3 trial data disappoint, leading to a sharp correction.
Key entities
- companyArgenx SE
Biopharmaceutical firm developing autoimmune disease therapies.
- analystWells Fargo
Set a $1,415 12‑month price target for ARGX.
- analystUBS
Set a $1,400 12‑month price target for ARGX.
